Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Effect of Liraglutide in Patients With Type 2 Diabetes and Severe Renal Insufficiency
Brief Summary: Incretin-based therapy for the treatment of patients with type 2 diabetes mellitus (T2D) is new and fundamentally different from the classical treatments with oral antidiabetic agents and insulin. The novel and original aspect of this investigator-initiated study is the focus on treatment with an incretin-based agent (the GLP-1 analogue liraglutide) in T2D patients with severely reduced kidney function. At present there is virtually no knowledge of the physiology and clinical implications of the role of incretin hormones and incretin-based therapy in this group of diabetic patients.The aim of the study is to establish an evidence-based rationale for introducing a GLP-1 analogue to the limited armamentarium of antidiabetic drugs for patients with type T2D and severe renal insufficiency. The overall hypothesis is that patients with T2D and severe renal insufficiency will tolerate and benefit from treatment with the GLP-1 analogue liraglutide, hereby improving glycaemic control and reducing risk factors of cardiovascular disease


Options:
A: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: Liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: BI 10773 low dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 low dose, Drug: Placebo BI 10773 high dose | Arm Label: BI 10773 high dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 high dose, Drug: Placebo BI 10773 low dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo BI 10773 high dose, Drug: Placebo BI 10773 low dose | Intervention Type: DRUG; Name: BI 10773 low dose; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BI 10773 high dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): BI 10773 low dose
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Intensive medical therapy, Procedure: Percutaneous Coronary Intervention (PCI) plus intensive medical therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intensive medical therapy | Intervention Type: PROCEDURE; Name: Intensive medical therapy; Assigned to Arm(s): 1, 2 | Intervention Type: PROCEDURE; Name: Percutaneous Coronary Intervention (PCI) plus intensive medical therapy; Assigned to Arm(s): 1
D: Arm Label: T2D, Dialysis, Liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: T2D, Dialysis, Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: T2D, Normal kidney function, Liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: T2D, Normal kidney function, Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Liraglutide | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): T2D, Dialysis, Liraglutide, T2D, Dialysis, Placebo, T2D, Normal kidney function, Liraglutide, T2D, Normal kidney function, Placebo

Answer: D